Story of our Export Journey

Since its inception from Pfizer Incorporation (Bangladesh), we designed a dream of establishing a global pharmaceutical company coming out of Bangladesh. Keeping that in mind, the management built a team with winning mentality, dedication and technical strength.

?

We started small, with only one facility based in Mirpur and also, we entered late in the export industry, but in a very short span of time we are on our way to become a truly multinational company from Bangladesh. From 01 to 14, the number of facilities increased with Stringent Regulatory Approvals like US FDA, UK MHRA, TGA, Health Canada, ANVISA and also approvals from other MOH which is pre-requisite to any market entry.

?

Our focus has always been to understand the R&D concept and slowly we built a team with international expertise and local brilliant minds. Right now, over 160 scientists working in our company to identify the new tools and techniques of drug development. The in-house capability to formulate molecules and file them in regulated, semi-regulated market so far has been a success. With a robust, young and passionate business team, we have successfully partnered with top global companies and on the verge of signing further big deals.

?

From Business point of view, we know the importance of entering and competing in the regulated markets and hence conducted 66 Bio-Equivalent studies. This is allowing us to file in the UK, EU, USA, Australia, Canada and Brazil. The most inspiring fact is, through these filings and approvals, we are now able to successfully inter the GCC region as well. Our priorities are not limited to these big markets only but we have been successful in partnering with global NGOs like UNICEF, DKT International and MSI Reproductive Choices to supply products across the globe.

?

Our expertise in Hormones and Reproductive Healthcare products has now extended to the global market. As one of the largest hormonal pharmaceutical manufacturers in the world, we have established ourselves as pioneers in solid dosage form and have recently developed expertise in the sterile segment. Our commitment to innovation and growth continues to position us as leaders in the industry.

?

Renata's global expansion has been fueled by a focus on niche and value-added in-house development, registration, and marketing. Collaborative contract manufacturing opportunities with global companies have also been a key factor. Renata's heavy investment in R&D has proven to be fruitful, with a belief that the ROI of such investments is always worth it.

?

We are focusing intensively in emerging markets as well with our strong presence in Sri Lanka, Myanmar, Kenya and slowly across Africa and APAC. Whereas exporting is the term we use for sending the goods, Renata believes in expansion of its image and brands. With dedicated team, brand building activities and gaining trust in the healthcare community, Renata's success has reached a new height.

?

Together, we have achieved a noticeable growth in our export business which will continue further. Renata limited has been awarded HSBC Business Excellence Award for non-traditional and emerging sector for its exemplary contribution in export for the fiscal year 2022-23. This will definitely inoculate as a motivation to expand Renata’s reach to all over the world with quality medicines and commitment for a safe and healthy future.